[
  {
    "ts": null,
    "headline": "REGN FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action - REGN",
    "summary": "WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. between November 2, 2023 and October 30, 2024, both dates inclusive , of...",
    "url": "https://finnhub.io/api/news?id=4dd25f261582870f30a082299ed52baaa87166c05a800850a8de254b42a1cda3",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740750663,
      "headline": "REGN FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action - REGN",
      "id": 132907222,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. between November 2, 2023 and October 30, 2024, both dates inclusive , of...",
      "url": "https://finnhub.io/api/news?id=4dd25f261582870f30a082299ed52baaa87166c05a800850a8de254b42a1cda3"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit",
    "summary": "LOS ANGELES, Feb. 28, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Regeneron Pharmaceuticals, Inc. have opportunity to lead the securities...",
    "url": "https://finnhub.io/api/news?id=c72472b051dbafbc4972d7f8f55496eca15f52e0d13dcdc6eb0b3d45be493264",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740744070,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit",
      "id": 132906485,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "LOS ANGELES, Feb. 28, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Regeneron Pharmaceuticals, Inc. have opportunity to lead the securities...",
      "url": "https://finnhub.io/api/news?id=c72472b051dbafbc4972d7f8f55496eca15f52e0d13dcdc6eb0b3d45be493264"
    }
  },
  {
    "ts": null,
    "headline": "Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma",
    "summary": "TARRYTOWN, N.Y., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of linvoseltamab to treat adults with relapsed and refractory (R/R) multiple myeloma (MM). The recommendation is specific to those who have received at least three prior therapies, including a proteasome inhib",
    "url": "https://finnhub.io/api/news?id=f0828ef146c1095e2ae6769d2fb772326ec77cce5331a42dd222b842e28b6c98",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740744000,
      "headline": "Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma",
      "id": 133186699,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "TARRYTOWN, N.Y., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of linvoseltamab to treat adults with relapsed and refractory (R/R) multiple myeloma (MM). The recommendation is specific to those who have received at least three prior therapies, including a proteasome inhib",
      "url": "https://finnhub.io/api/news?id=f0828ef146c1095e2ae6769d2fb772326ec77cce5331a42dd222b842e28b6c98"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Gets CHMP Backing of Linvoseltamab in Multiple Myeloma",
    "summary": "By Colin Kellaher Regeneron Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended conditional marketing approval of linvoseltamab for...",
    "url": "https://finnhub.io/api/news?id=279dd71a6e8a91f59f435dab37fdf9bef0c8eeb5d1a9b0dc0cb480ce58bf8c53",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740729014,
      "headline": "Regeneron Gets CHMP Backing of Linvoseltamab in Multiple Myeloma",
      "id": 132904954,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Regeneron Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended conditional marketing approval of linvoseltamab for...",
      "url": "https://finnhub.io/api/news?id=279dd71a6e8a91f59f435dab37fdf9bef0c8eeb5d1a9b0dc0cb480ce58bf8c53"
    }
  },
  {
    "ts": null,
    "headline": "Drug Stocks Are the New Safe Bet in a Shaky Market",
    "summary": "Drug Stocks Are the New Safe Bet in a Shaky Market",
    "url": "https://finnhub.io/api/news?id=9cbf52ef07edbc5bfcfb2610a217677b7f12f0522f3e65f5864ff7326854f3b8",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740726000,
      "headline": "Drug Stocks Are the New Safe Bet in a Shaky Market",
      "id": 132907806,
      "image": "",
      "related": "REGN",
      "source": "DowJones",
      "summary": "Drug Stocks Are the New Safe Bet in a Shaky Market",
      "url": "https://finnhub.io/api/news?id=9cbf52ef07edbc5bfcfb2610a217677b7f12f0522f3e65f5864ff7326854f3b8"
    }
  },
  {
    "ts": null,
    "headline": "Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN",
    "summary": "NEW YORK, Feb. 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. of a class action securities lawsuit. ...",
    "url": "https://finnhub.io/api/news?id=c4a84a2ec0b074fa4f27819e68bfc892f57e80399cde905b9c914a19f05c0a0a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740721580,
      "headline": "Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN",
      "id": 132904212,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "NEW YORK, Feb. 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. of a class action securities lawsuit. ...",
      "url": "https://finnhub.io/api/news?id=c4a84a2ec0b074fa4f27819e68bfc892f57e80399cde905b9c914a19f05c0a0a"
    }
  },
  {
    "ts": null,
    "headline": "First Circuit Embraces More Restrictive View Of False Claims Act Kickback Enforcement Provision",
    "summary": "The United States Court of Appeals for the First Circuit's opinion in United States v. Regeneron Pharmaceuticals, Inc. has sharpened the circuit split for demonstrating the effect of a kickback on...",
    "url": "https://finnhub.io/api/news?id=fb14699ffcd87fbba038a40e4581a743f7027d653e54ec2e8c40e77543bf5d05",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740712214,
      "headline": "First Circuit Embraces More Restrictive View Of False Claims Act Kickback Enforcement Provision",
      "id": 132903420,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "The United States Court of Appeals for the First Circuit's opinion in United States v. Regeneron Pharmaceuticals, Inc. has sharpened the circuit split for demonstrating the effect of a kickback on...",
      "url": "https://finnhub.io/api/news?id=fb14699ffcd87fbba038a40e4581a743f7027d653e54ec2e8c40e77543bf5d05"
    }
  },
  {
    "ts": null,
    "headline": "First Circuit Adopts \"But For\" Causation Standard Under The Anti-Kickback Statute, Paving The Way For Potential Supreme Court Review",
    "summary": "Last week, the First Circuit Court of Appeals issued its long-awaited decision in United States v. Regeneron Pharmaceuticals1 with significant implications for health care companies facing allegations...",
    "url": "https://finnhub.io/api/news?id=b9f77e7d7833b0f82bfe08bbdac0df3bccc9702095091c23e2484988b89902e4",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740712214,
      "headline": "First Circuit Adopts \"But For\" Causation Standard Under The Anti-Kickback Statute, Paving The Way For Potential Supreme Court Review",
      "id": 132903419,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "Last week, the First Circuit Court of Appeals issued its long-awaited decision in United States v. Regeneron Pharmaceuticals1 with significant implications for health care companies facing allegations...",
      "url": "https://finnhub.io/api/news?id=b9f77e7d7833b0f82bfe08bbdac0df3bccc9702095091c23e2484988b89902e4"
    }
  },
  {
    "ts": null,
    "headline": "Circuit Split Deepens On Anti-Kickback Statute's Causation Standard",
    "summary": "Introduction: In its recent decision in United States v. Regeneron Pharmaceuticals, Inc., the United States Court of Appeals for the First Circuit deepened an existing federal circuit court split...",
    "url": "https://finnhub.io/api/news?id=c409206c220709a74146e0a28f5958b0ae2bd0da84c2c0349cef538fbd58429e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740712213,
      "headline": "Circuit Split Deepens On Anti-Kickback Statute's Causation Standard",
      "id": 132903422,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "Introduction: In its recent decision in United States v. Regeneron Pharmaceuticals, Inc., the United States Court of Appeals for the First Circuit deepened an existing federal circuit court split...",
      "url": "https://finnhub.io/api/news?id=c409206c220709a74146e0a28f5958b0ae2bd0da84c2c0349cef538fbd58429e"
    }
  }
]